Targeting Myotonic Dystrophy Type 1 with Metformin

García-Puga, Mikel; Saenz-Antoñanzas, Ander; Matheu, Ander; López de Munain, Adolfo

doi:10.3390/ijms23052901

Open AccessReview

Targeting Myotonic Dystrophy Type 1 with Metformin

by

Mikel García-Puga

^1,2,3

,

Ander Saenz-Antoñanzas

²,

Ander Matheu

^2,4,5,* and

Adolfo López de Munain

^1,3,6,7,*

¹

Neuromuscular Diseases Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain

²

Cellular Oncology Group, Biodonostia Health Research Institute, 20014 San Sebastian, Spain

³

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED-CIBER), Carlos III Institute, 28031 Madrid, Spain

⁴

Basque Foundation for Science (IKERBASQUE), 48009 Bilbao, Spain

⁵

Centro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludable (CIBERfes), Carlos III Institute, 28029 Madrid, Spain

⁶

Neurology Department, Donostia University Hospital, OSAKIDETZA, 20014 San Sebastian, Spain

⁷

Department of Neurosciences, Faculty of Medicine and Nursery, University of the Basque Country, 20014 San Sebastian, Spain

^*

Authors to whom correspondence should be addressed.

Int. J. Mol. Sci. 2022, 23(5), 2901; https://doi.org/10.3390/ijms23052901

Submission received: 24 January 2022 / Revised: 28 February 2022 / Accepted: 2 March 2022 / Published: 7 March 2022

(This article belongs to the Special Issue Myotonic Dystrophy: From Molecular Pathogenesis to Therapeutics 2.0)

Download

Browse Figure

Versions Notes

Abstract

Myotonic dystrophy type 1 (DM1) is a multisystemic disorder of genetic origin. Progressive muscular weakness, atrophy and myotonia are its most prominent neuromuscular features, while additional clinical manifestations in multiple organs are also common. Overall, DM1 features resemble accelerated aging. There is currently no cure or specific treatment for myotonic dystrophy patients. However, in recent years a great effort has been made to identify potential new therapeutic strategies for DM1 patients. Metformin is a biguanide antidiabetic drug, with potential to delay aging at cellular and organismal levels. In DM1, different studies revealed that metformin rescues multiple phenotypes of the disease. This review provides an overview of recent findings describing metformin as a novel therapy to combat DM1 and their link with aging.

Keywords: myotonic dystrophy; metformin; therapeutic strategies; aging

Share and Cite

MDPI and ACS Style

García-Puga, M.; Saenz-Antoñanzas, A.; Matheu, A.; López de Munain, A. Targeting Myotonic Dystrophy Type 1 with Metformin. Int. J. Mol. Sci. 2022, 23, 2901. https://doi.org/10.3390/ijms23052901

AMA Style

García-Puga M, Saenz-Antoñanzas A, Matheu A, López de Munain A. Targeting Myotonic Dystrophy Type 1 with Metformin. International Journal of Molecular Sciences. 2022; 23(5):2901. https://doi.org/10.3390/ijms23052901

Chicago/Turabian Style

García-Puga, Mikel, Ander Saenz-Antoñanzas, Ander Matheu, and Adolfo López de Munain. 2022. "Targeting Myotonic Dystrophy Type 1 with Metformin" International Journal of Molecular Sciences 23, no. 5: 2901. https://doi.org/10.3390/ijms23052901

APA Style

García-Puga, M., Saenz-Antoñanzas, A., Matheu, A., & López de Munain, A. (2022). Targeting Myotonic Dystrophy Type 1 with Metformin. International Journal of Molecular Sciences, 23(5), 2901. https://doi.org/10.3390/ijms23052901

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Targeting Myotonic Dystrophy Type 1 with Metformin

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI